Compare CWBC & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWBC | OCGN |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.6M | 387.3M |
| IPO Year | 1996 | N/A |
| Metric | CWBC | OCGN |
|---|---|---|
| Price | $23.01 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.33 | $7.00 |
| AVG Volume (30 Days) | 179.3K | ★ 3.7M |
| Earning Date | 01-24-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | ★ 309.32 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $138,038,000.00 | $5,370,000.00 |
| Revenue This Year | $32.04 | $32.40 |
| Revenue Next Year | $7.24 | N/A |
| P/E Ratio | $12.89 | ★ N/A |
| Revenue Growth | ★ 45.08 | 14.26 |
| 52 Week Low | $15.57 | $0.52 |
| 52 Week High | $24.37 | $1.90 |
| Indicator | CWBC | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 55.47 |
| Support Level | $22.63 | $1.35 |
| Resistance Level | $24.37 | $1.58 |
| Average True Range (ATR) | 0.49 | 0.09 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 21.90 | 55.68 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the Company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").